drugset / Trial / NCT07712692
Evaluation of NWRD09 for HPV-16 Related Cervical HSIL
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD09 administered by intramuscular (IM) injection in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) associated with human papillomavirus (HPV) 16.
Timeline
- Start
- 2026-08-01
- Primary completion
- 2027-06-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NWRD09 | Messenger RNA (mRNA) | 10 ug | Intramuscular |
| Subject | NWRD09 | Messenger RNA (mRNA) | 20 ug | Intramuscular |